Pharmacokinetics of [125I]-recombinant human interleukin-11:: 1.: Absorption, distribution and excretion after subcutaneous administration to male rats

被引:4
|
作者
Uchida, T
Aoyama, K
Mori, K
Usui, T
Watanabe, T
Takariki, Y
Asahara, N
Hirose, M
Kimura, T
Tateishi, M
Higuchi, S
机构
[1] Yamanouchi Pharmaceut Co Ltd, Drug Metab Labs, Itabashi Ku, Tokyo 1748511, Japan
[2] Nemoto & Co Ltd, Life Sci Lab, Tsukuba Lab, Ibaraki, Osaka, Japan
关键词
recombinant human interleukin-11; subcutaneous administration; absorption; metabolism; disposition;
D O I
10.1007/BF03192301
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Absorption, distribution, metabolism and excretion of [I-125]-rhTL-11 (recombinant human interleukin-11) after subcutaneous administration in rats were investigated. After a single administration, the concentration of radioactivity in the tissues was 2-6-fold higher in the liver and kidneys, and slightly higher in the gastrointestinal tract as compared to the plasma concentration. However, since the concentration in the other tissues was lower than the plasma concentration, the transport of rhIL-11 into tissues appeared to be low. Tissue radioactivity rapidly diminished, thus accumulation of rhIL-11 in tissues was thought to be low. Excretion of radioactivity into urine and feces was almost complete 72 h after administration, with 88.5% of the dosed radioactivity being found in urine and 7.9% in feces. When [I-125]-rhIL-11 was administered to bile-duct cannulated rats, 44.4% of the dosed radioactivity was excreted into bile up to 48 h after administration. Most radioactivity in bile and urine was found in the TCA supernatant and low molecular weight fraction by HPLC analysis, indicating that rhIL-11 was eliminated from the body by metabolism.
引用
收藏
页码:403 / 410
页数:8
相关论文
共 15 条
  • [11] Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate - 1st communication: Absorption, distribution and excretion after single administration of C-14-labeled compound to rats and dogs
    Nakamura, A
    Sugihara, K
    Hirota, T
    Morino, A
    Ezumi, Y
    Takaichi, M
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1997, 47 (02): : 151 - 159
  • [12] Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoic acid - 1st communication: Absorption, distribution, metabolism and excretion after topical application and subcutaneous administration in rats
    Mizojiri, KJ
    Okabe, H
    Sugeno, K
    Esumi, Y
    Takaichi, M
    Miyake, T
    Seki, H
    Inaba, A
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1997, 47 (01): : 59 - 69
  • [13] STUDY ON THE METABOLIC-FATE OF CATENA-(S)-(MU-(N-ALPHA-(3-AMINOPROPIONYL)HISTIDINATO(2-)-N1,N2,O-N-TAU)-ZINC) .1. ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION AFTER SINGLE ADMINISTRATION TO RATS
    SANO, H
    FURUTA, S
    TOYAMA, S
    MIWA, M
    IKEDA, Y
    SUZUKI, M
    SATO, H
    MATSUDA, K
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1991, 41-2 (09): : 965 - 975
  • [14] Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid - 2nd communication: Absorption, distribution and excretion after single and consecutive subcutaneous administration in rats
    Mizojiri, K
    Okabe, H
    Sugeno, K
    Esumi, Y
    Takaichi, M
    Tsutsumi, S
    Harada, T
    Miyoshi, R
    Inaba, A
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1997, 47 (02): : 195 - 200
  • [15] STUDY ON THE METABOLIC-FATE OF CATENA-(S)-(MU-(N-ALPHA-(3-AMINOPROPIONYL)HISTIDINATO(2-)-N1,N2,O-N-TAU)-ZINC) .2. ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION AFTER REPEATED ADMINISTRATION TO RATS
    TOYAMA, S
    FURUTA, S
    MIWA, M
    SUZUKI, M
    SANO, H
    MATSUDA, K
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1991, 41-2 (09): : 976 - 983